BRCA1 and cancer: Also, germline BRCA1/2 mutations were an independent predictive factor for the development of RDR, while patients harboring germline BRCA1 mutant tumors had worse outcomes to PARP inhibitors relative to patients with BRCA2 mutant cancers.